METHODS FOR OBTAINING STEM CELLS
20170086453 ยท 2017-03-30
Inventors
- Fabrice CHRETIEN (Paris, FR)
- Mathilde Latil (Saint Maur des Fosses, FR)
- Shahragim Tajbakhsh (Paris, FR)
Cpc classification
A61K2035/124
HUMAN NECESSITIES
A61K35/34
HUMAN NECESSITIES
A61K35/28
HUMAN NECESSITIES
C12N5/0668
CHEMISTRY; METALLURGY
A01N1/162
HUMAN NECESSITIES
C12N5/0647
CHEMISTRY; METALLURGY
International classification
A61K35/34
HUMAN NECESSITIES
Abstract
The present invention relates to methods for obtaining stem cells from mammalian cadavers, methods for obtaining or purifying stem cells from a sample likely to contain non-stem cells, methods of regeneration of injured tissues and methods of treatment.
Claims
1-30. (canceled)
31. A method for culturing mammalian stem cells comprising using an anaerobic cell culture system for culturing isolated mammalian stem cells at an oxygen concentration equal to or less than 0.1% and at a temperature of 1-6 C. during a period of time of at least 2 days.
32. The method according to claim 31, wherein mammalian stem cells are cultured at 1-6 C. for 2 days to 30 days.
33. The method according to claim 31, wherein the mammalian stem cells are hematopoietic stem cells, neural stem cells or muscle stem cells.
34. The method according to claim 31, wherein isolated mammalian stem cells are cultured at an oxygen concentration equal to or less than 0.1% and at a temperature of 1-6 C. during a period of time of at least 4 days.
35. A method for regenerating an injured tissue in a subject in need thereof, said method comprising: a) maintaining a biological material which usually comprises stem cells at an oxygen concentration equal to or less than 0.1% and at a temperature of 1-6 C.; b) obtaining stem cells by selecting viable cells, wherein viable cells are stem cells; and c) administering the stem cells obtained at step b) to said subject.
36. The method according to claim 35, wherein the stem cells are mammalian stem cells and wherein, at step c), the stem cells are transformed or transfected with a vector, especially a vector of expression, or transduced with a virus vector, said vector comprising at least one polynucleotide sequence of interest, before being administered to said subject.
37. A method for regenerating an injured tissue in a subject in need thereof, said method comprising: a) maintaining a biological material which usually comprises stem cells at an oxygen concentration equal to or less than 0.1%, wherein the biological material is muscle sample, especially skeletal or smooth muscle sample; b) obtaining stem cells by selecting viable cells, wherein viable cells are muscle stem cells; and c) administering the stem cells obtained at step b) to said subject.
38. A method for regenerating an injured tissue in a subject in need thereof, said method comprising: a) maintaining a biological material which usually comprises stem cells at an oxygen concentration equal to or less than 0.1%, wherein the biological material is selected from the group consisting of brain, spinal cord and meninges sample; b) obtaining stem cells by selecting viable cells, wherein viable cells are neural stem cells; and c) administering the stem cells obtained at step b) to said subject.
39. A method according to claim 37, wherein the stem cells are mammalian stem cells, and wherein, at step c), the stem cells are transformed or transfected with a vector, especially a vector of expression, or transduced with a virus vector, said vector comprising at least one polynucleotide sequence of interest, before being administered to said subject.
40. A method according to claim 38, wherein the stem cells are mammalian stem cells, and wherein, at step c), the stem cells are transformed or transfected with a vector, especially a vector of expression, or transduced with a virus vector, said vector comprising at least one polynucleotide sequence of interest, before being administered to said subject.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0161] The present invention will be further illustrated by the additional description and drawings which follow, which refer to examples illustrating the obtaining of stem cells from cadavers, the enrichment of stem cells by maintaining them at 4 C. in the absence of oxygen and the use of hematopoietic stem cells and muscle stem cells obtained by this method of enrichment for regenerating bone marrow of irradiated mice or skeletal muscle of mice. It should be understood however that these examples are given only by way of illustration of the invention and do not constitute in anyway a limitation thereof.
[0162]
[0163]
[0164]
[0165]
[0166]
[0167]
[0168]
[0169]
[0170]
[0171]
[0172]
[0173]
[0174]
[0175]
[0176]
[0177]
[0178]
[0179]
[0180]
[0181] These experiments demonstrate the ability of cadaver bone marrow to fully reconstitute blood compartment.
[0182]
[0183]
[0184]
[0185]
[0186]
[0187]
[0188]
[0189]
DETAILED DESCRIPTION OF THE INVENTION
Example I. Material and Methods
Ethical
[0190] Human samples were collected according to guidelines recommended by the national ethical committee.
[0191] All mice were housed in a level 2 biosafety animal facility, and received food and water ad libitum. Prior to manipulations, animals were anaesthetized using intraperitoneal injection of Ketamine and Xylazine (respectively 25% and 12.5% in PBS). This study was conducted in accordance with the local and EC guidelines for animal care (Journal Officiel des Communauts Europennes, L358, Dec. 18, 1986).
[0192] Mouse Strain
[0193] C57BL/6 mice (Ma-Credo, L'arbresle, France), Tg:Pax7-nGFP mice in which satellite cells can be easily visualize by their GFP expression (Sambasivan R, Dev Cell. 2009 June; 16(6):810-21), Pax7.sup.nlacZ/+ mice in which satellite cells can be easily visualize by their LacZ expression (Ramkumar Sambasivan and Shahragim Tajbakhsh unpublished), Tg:Pax7-nGFP::Tg:CAG:PLAP (Sambasivan 2009) in which all cells constitutively express placental alkaline phosphatise and satellite cell GFP, Tg: CAG-GFP mice (C57BL/6 TgN[actEGFP]Osb YO1) in which the GFP transgene is ubiquitinously expressed under the control of a non-tissue specific promoter, chicken beta-actin with cytomegalovirus enhancer, as a cytoplasmic protein (Okabe, et al, FEBS Lett. 1997 May 5; 407(3):313-9).
[0194] Tissue Preparation
[0195] Depending of the condition used, after animal sacrifice, tissues were snap-frozen immediately in liquid nitrogen-cooled isopentane for immunohistochemistry and histological analysis, or fixed using buffered 4% paraformaldehyde prior to cryopreservation in 30% sucrose overnight at 4 C. (a procedure that keep the spontaneous fluorescence of GFP in a tissue section). Serial 7 m thick cryosections were performed for analysis.
[0196] Images were captured on a Zeiss Axiophot microscope with an Apotome (Carl Zeiss Inc., Germany) and Orca ER digital camera (Hamamatsu Photonics, Japan) using Simple PCI (C-Imaging, Compix Inc) software.
[0197] Immunohistochemistry
[0198] For human cases, 5 m cryosections of muscles from cadavers were immunostained with mouse anti-human CD56 (1:20 dilution; NHK-1-RD1; Beckman Coulter) and revealed using peroxidase Vectastain ABC kit (Vector Laboratories).
[0199] For mouse tissues, immunostainings were done without antigen unmasking. The following protocol was always used: after rehydratation of sections with PBS, non-specific protein binding was blocked with 20% goat serum and cells were permeabilised with 0.5% triton-X100 (Sigma-Aldrich, St-Louis, Mo.) 20 minutes. Incubation with primary antibody was done overnight at 4 C., and signal was revealed with secondary antibody incubated 1 hour at 37 C.
[0200] Dako Diluent buffer (Dako, Glostrup, Denmark) was used for diluting antibodies.
[0201] The following antibodies were used as primary: mouse monoclonal antibodies against human Placental Alkaline Phosphatase [8B6] (1:300, GenTex, Irvine, Calif.), M-cadherin (1:50, Alexis Biochemicals, Lausen, Switzerland), myogenin (1:50, BD Pharmingen, San Jose, Calif.), rabbit polyclonal anti-human (or mouse) desmin (1:50, Abcam, Cambridge, UK), rabbit polyclonal antibodies against mouse myogenin (1:50, Santa Cruz biotechnologies, Santa Cruz, Calif.) and Laminin-1 (1:50, Sigma-Aldrich, Saint-Louis, Mo.).
[0202] The secondary antibodies used was Cy3 conjugated donkey anti-mouse (1:400, Jackson lmmunoresearch lab., Baltimore, Pa.), FITC conjugated goat anti-mouse (1:200, Jackson), Cy3 conjugated donkey anti-rabbit (1:200, Jackson), biotinilated horse anti-mouse (1:200, Vector laboratories, Burlingame, Calif.), Cy5 conjugated donkey anti-rabbit (1:200, Jackson), FITC conjugated donkey anti-goat (1:200, Jackson) and DTAF conjugated-streptavidin (1:400, Immunotech Beckman, Brea, Calif.).
[0203] X-Gal Staining
[0204] Cytocentrifuged cells were rehydrated with PBS before fixation with PFA 4% followed by overnight incubation with X-Gal 40 mg/ml (reconstitute in Dimthylsulfoxide, Invitrogen, Paisley, UK) in a solution containing 4 mM each of potassium ferrocyanide, potassium ferricyanide, 2 mM MgCl, and 0.02% NP40 in PBS at 37 C.
[0205] Bone Marrow Transplantation
[0206] Briefly, donor BM cells were obtained by flushing 2 femurs of donor mice (various times post mortem) with RPMI medium (Invitrogen, Paisley, UK) and 0.1% heparin (Choay 5000 Ul/ml). In the case of late post-mortem cadavers the BM cell suspension was incubated with 50 g/ml DNAse I (Roche, Mannheim, Germany)I to preclude clogging of cells. After washing, retro-orbital injection of cells was done in 0.1 ml fresh mouse serum and Hanks Buffer (PAA Laboratories GmbH, Pasching, Austria) (1:1), in 9.5 Gy-irradiated, 4 week-old B6 mice (.sup.60Co rays within 1 day before BM transplantation). After transplantation, mice received 10 mg/kg/day ciprofloxacin for 10 days to prevent infection during the aplastic phase.
[0207] Flow Cytometry Analysis
[0208] To quantify the amount of engraftment, the peripheral blood mononuclear cells of transplanted mice were analyzed by flow cytometry using a Cyan cytometer (DakoCytomation, Glostrup, Denmark) 1 month post-transplantation. Red blood cells were lysed using ACK buffer (NH.sub.4Cl 0.15M, KHCO.sub.3 1 mM, Na.sub.2EDTA 0.1 mM) and immunostainings were done at +4 C. for 30 mn using rat anti mouse CD16/CD32 (Mouse BD Fc Block) (BD Biosciences) to preclude cell activation and adherence to plastic. In all the FC experiment cells were also labelled with Propidium Iodide 1 mg/ml (Sigma-Aldrich, St-Louis, Mo.) to exclude dead cells from analysis.
[0209] Leukocytes were gated on, and GFP fluorescence was measured under the fluorescein isothiocyanate channel. Specific fluorescence stainings were done using PE-Cy5-conjugated anti-Ly-6C (Gr1) (eBioscience San diego, USA), PE-conjugated anti-CD11 b (eBioscience San diego, USA), PE-conjugated anti-CD5 (BD Biosciences), PE-conjugated anti-B220 (BD Biosciences), Abs and their respective isotypes. All analyses and quantitation were performed using Summit v4.3 software from DakoCytomation.
[0210] For the assessment of active mitochondria immediately after isolation of cells by FACS Mitotracker (invitrogen, M22246) deep red at 500 nM was used for 30 minutes at 37 C. Then the intensity of far red staining was analysed.
[0211] ATP Level Measurement
[0212] For measuring the levels of ATP, cells were isolated by FACS directly in lysis buffer and maintained at 4 C. An ApoSENSOR kit from biovision (Catalog #K254-200, -1000) was used to measure ATP levels where luciferin reacts with ATP and emits signal in proportion to ATP content; emitted light was measured using luminometer (GLOMAX 20/20 luminometer promega).
[0213] FACS Cell Sorting and Analysis
[0214] MoFlo Legacy (Beckman Coulter, Brea, Calif.) was used for cell sorting and CyAn ADP for cell analysis (Beckman Coulter).
[0215] Cell Suspension Preparation from Muscle Tissue
[0216] After sacrifice, muscles from mice were carefully dissected, minced in small pieces and washed in PBS before digestion with Pronase (protease from streptomyces griseus (Sigma-Aldrich, St-Louis, Mo.) reconstituted in DMEM with penicillin Streptomycin 0.4%). All supernatants were collected and enzyme activity immediately blocked by adding 20% foetal calf serum. This procedure was performed serially until complete digestion of the tissue (4 to 5 rounds of 20 minutes digestion at 37 C.). Cells were then washed and filtered with a 40 m cell strainer before 10 minutes treatment with an antibiotic/antifungus cocktail.
[0217] Cell Cultures
[0218] Unless otherwise indicated, culture media components were obtained from GIBCO (Invitrogen, Paisley, UK) and culture plastics were obtained from TPP (Trasadingen, Switzerland). Human or mouse muscle cells were cultured from muscle samples as described previously (Chazaud et al., 2000). In standard conditions (spontaneous in vitro myogenesis), cells were grown in Ham's F12 medium containing 20% FCS (growing medium) 1% UltroserG (PALL Life Sciences, Saint Germain en Laye, France), 0.2% Vitamins, 1% non essentials amino acids 100, 0.4% Penicillin Streptomycin 10000 U/ml without serum withdrawal. In differentiating conditions, growing medium was replaced by Ham's F12 medium containing 5% FCS (differentiating medium) at time of subconfluence.
[0219] For culture without oxygen, GenBag (Biomerieux, Craponne, France) devices were used.
[0220] RNA Extraction, RT and qPCR
[0221] Total RNA was extracted from cells isolated by FACS on GFP positivity directly in lysis buffer using the Quiagen RNAeasy Micro purification Kit. 400-600 ng of DNAse-treated (Roche). RNA was processed for random-primed reverse transcripion using the SuperScript II reverse transcriptase protocol of Invitrogen. The cDNAs were then analyzed by real-time PCR using Taqman universal Master Mix and an ABI Prism 7700 (Perkin-Elmer Applied Biosystems) and a StepOnePlus (Applied Biosystems). TBP reference transcript levels were used for the normalisation of each target within each sample (=CT). Custom primers were designed using the Primer3Plus online software.
[0222] Statistical Analysis
[0223] In all experiments the n value was at least 5. The t test was used for statistical analyses (GraphPad-InStat software). P<0.05 was considered significant.
Example II. Stem Cells Survive for Extended Periods Post Mortem
[0224] To determine how long muscle cells would survive in dead tissue, human cadavers were obtained from the centre du don des corpsFacult de Mdecine Paris Descartes. After death, cadavers were store at 4 after an initial and variable period lasting from several hours to 24 hours at room temperature. In all cases (n=16) patients were from 57-95 y.o. in age (mean 84 y.o.). A deltoid muscle biopsy (2 grams) was performed from 6-17 days post mortem. None of the patients were suffering from neoplasia. Histological analysis of the muscle showed a necrotic appearance and chromatin from myonuclei usually appeared leaky. CD56 immunostaining which labelled satellite cells (SCs) (i.e. muscle tem cells) in human showed a few positive cells were not necrotic, but they exhibited a compact appearance.
[0225] Mononuclear cells were extracted from muscle biopsies using standard protocols (Chazaud B, et al. Exp Cell Res. 2000; 258: 237-44.) and cultured for two weeks in gelatin coated dishes and in a classical medium composed with HamF12, 20% fetal calf serum, 0.4% penicillin/streptomycin, 1% ultroserG, 0.2% vitamin, 1% non essential amino-acids. In all cases, including latepost mortem time point (17 days), after a maximum of 4 days, a few cells were observed that were attached to the bottom of the dish. They grew slowly from small colonies and when the density reached a critical threshold, some cells align to fuse. Two weeks post plating, differentiating medium (HamF12, 5% normal horse serum, 0.4% penicillin/streptomycin, 0.2% vitamin, 1% non essential amino-acids) was added to the culture and cell fused forming numerous myotubes.
[0226] Immunostainings confirm that more than 90% of the attached cells forming small colonies were expressing the myogenic marker Desmin. This was also the case at later stages when these cells fused and differentiated into myotubes, expressing both Desmin and the differentiation transcription factor Myogenin. Due to the extensive decomposition of tissues, we were not able to obtain cadavers after 17 days post mortem.
[0227] To test the survival potential of SCs in muscle samples, we take advantage of organ donors with beating heart in who we perform a surgical muscle biopsy. These Donors were younger in age (n=15; from 41-77 y.o., mean 57 y.o.). We kept the muscle sample in a buffered medium (DMEM, 1 mM HEPES, 0.4% penicillin/streptomycin), at 4 C. in a sealed container. The time of tissue sampling (i.e. number of days between the sampling and the culture) was noted (see Table I below).
TABLE-US-00001 TABLE I D2 D4 D6 D10 D14 D20 D25 D30 D35 D40 D50 D55 D60 D77 F 56 y.o. + + + F 58 y.o. + + F 43 y.o. + + M 50 y.o. F 59 y.o. + + F 57 y.o. + + + + F 74 y.o. + M 69 y.o. + + + + + M 55 y.o. F 43 y.o. + + + M 65 y.o. + + M 54 y.o. M 55 y.o. + + F 41 y.o F 77 y.o + +
[0228] As observed in cadavers, and from day 4 post-biopsy, muscle exhibited a necrotic appearance with some remaining CD56 immunopositive and other compact small cells adjacent to myofibers. Depending of the size of the sample, culturing muscle cells was possible many days after sampling. The samples were assayed regularly from day 2-77. Prior to day 30 post-sampling, the cultured cells yielded large numbers of cells, the majority (>80%) being myogenic as assessed by the formation of myotubes that expressed Myogenin and Desmin. After 35 days post-sampling viable cells were no longer obtained (assayed for 15 days in culture).
[0229] Similar results were obtained with mouse cadavers. C57BL6 mice (n=10 per time point) were sacrificed using CO.sub.2 and kept for several days at 4 C. (
Example III. Characterisation of Cell Types that Survive after Organismal Death
[0230] To determine if stem cells have a greater capacity to survive after organismal death, cell suspensions obtained from cadavers were stained with calcein that labels only live cells and evaluated the number of cells that remained alive by flow cytometry (FC). As shown in
[0231] To determine the number of viable SCs in a tissue after organism death, the Tg:Pax7nGFP mice were used in order to take advantage that all their satellite cells are GFP-positive and that SCs could be prospectively isolated by FACS based on GFP epifluorescence (Sambasivan R, Dev Cell. 2009 June; 16(6):810-21). The number of SCs in one Tibialis anterior (TA) muscle was enumerated every four days after death from 8 week old mice kept at 4 C. As shown in
[0232] To determine the proportion of SCs that survive after death, the knock-in mouse Pax7.sup.nlacZ/+ was used. In this mouse, bacterial lacZ reporter gene expression reflects the expression of the Pax7 gene in all satellite cells (R. Sambasian and S. Tajbakhsh, unpublished). Between day 0 and day 4 post mortem, the proportion of X-gal positive cells increased by 3.4 fold (see
[0233] To investigate the mechanism that permits muscle stem cells to survive after organismal death, it was examined whether cellular quiescence conferred a survival advantage compared to proliferating cells. To do this, we counted SCs from Tg:Pax7-nGFP in juvenile mice before SCs entered quiescence (growth paradigm). At P10 (10 days postnatal), satellite cells proliferate actively and myofibres continue to increase in size due to the addition of nascent myoblasts (Shinin V, et al. Nat Cell Biol. 2006 July; 8(7):677-687; White R B, et al. BMC Dev Biol. 2010 22; 10:21). In this scenario, no significant drop in SCs number between day 0 and day 4 post mortem (
[0234] To confirm that quiescent state might confer a survival advantage to the stem cells, three cohorts of mice were examined. In the first, satellite cells were enumerated from uninjured TA muscle of Tg:Pax7-nGFP mice at 4 days post mortem (1980212 GFP.sup.+/TA; n=5 mice; see
Example IV. Characterisation of Viable Cells after Organismal Death
[0235] To characterise the surviving SCs sub-population after death in mouse skeletal muscle, RT-qPCR were performed on purified satellite cells isolated by FACS and lysed directly in buffer. A library of cDNA was synthesized by reverse transcription and real time PCR (Taqman) was performed to assess the gene expression level of key satellite cell genes. The level of Pax7 and MyoD were similar in surviving cells day 4 and day 8 post mortem vs. cells extracted immediately after death (n=5) (
[0236] Further, these data clearly show that the post mortem derived muscle stem cells are characterized by a lack of detectable expression of Myogenin gene, while muscle stem cells extracted immediately after death (which is considered as representing cells present in a living subject) do express myogenin.
[0237] To assess the functional potential of surviving satellite cells, clonal analysis of cells sorted from Tg:Pax7-nGFP mice was performed. The percentage of clonogenicity (i.e. percentage of cell forming colonies after FACS in a 96 well plate) was not significantly different between day 0 and day 4 post mortem (20% vs. 16.3%) but this value drops dramatically at day 8 post mortem (1.6%)(
[0238] To characterize further the sub-population of resisting cells in a hostile environment, their energizing state was measured by assessing the mitochondrial number and activity, as well as ATP level in SCs 4 days post mortem. To do this, SCs were isolated by FACS from Tg:Pax7-nGFP mice from day 0, day 4 and day 8 animals post mortem. Staining with Mitotracker allowed assessing the number of active mitochondria in the different conditions by flow cytometry. The number of active mitochondria was significantly diminished in post mortem samples compared to live control adult animals. Interestingly, as shown in
[0239] Taken together these results reveal a direct correlation between the energizing threshold of the cell, presumably to ensure essential basal cellular activity and maintain viablilty, and the capacity to resist to a hostile environment. Cells exhibiting values below this threshold are not viable. These readouts provide insights into the mechanisms that allow these stem cells to survive after organismal death, and they provide a powerful tool to be used in diagnostic and therapeutical purposes.
[0240] To determine if stem cells have the functional capacity to regenerate a tissue after transplantation, SCs were extracted 4 days post mortem and engrafted into preinjured regenerating skeletal muscles of immunocompromised Rag1/2.sup./:.sub.C.sup./ recipient mice. Donor mice were double transgenic Tg:Pax7-nGFP::Tg:CAG-PLAP (PLAP, human alkaline phosphatase) mice to prospectively isolate satellite cells by FACS using GFP. The ubiquitous reporter PLAP permits to follow the fate of the engrafted cells.
[0241] In all the cases a significant contribution to regenerating skeletal muscle by the donor population was observed. After engrafting 10,000 SCs extracted from day 4 post-mortem mice, a mean of 300 PLAP-expressing myofibers were obtained. This result is similar to what is observed using control freshly isolated satellite cells.
Example V. Assessment of the Viability and Engraftment Potential of Haematopoietic Stem Cells Isolated from Mice Post Mortem
[0242] To determine if this extreme resistance to post mortem conditions is only the case for skeletal muscle stem cells, or another stem cell population behaves in a similar manner, hematopoietic stem cells were studied. At daily intervals post mortem, the bone marrow (BM) of Tg:CAG-GFP mouse femur was flushed (two limbs) and kept at 4 C. BM transplantations were performed in lethally irradiated C57BL6 recipient mice. The engraftment potential of transplanted BM progenitors was assessed by the percentage of GFP+ leukocytes found in the circulating blood. Using, 2, 3 and 4 days post mortem BM, blood cells were readily and fully reconstituted by BM progenitors in lethally irradiated recipients (n>5 in each case). Viability was ensured with all the animals that received a BM transplantation except when using BM from 4 days post mortem where viability was 60% (
[0243] To determine if the cells that were extracted from post mortem BM contained long term hematopoietic stem cells, a serial transplantation was performed with the grafted BM. GFP+ cells from the bone marrow of previously grafted animals were isolated by FACS 2 months after the first transplantation and re-grafted in lethally irradiated recipients. In all the cases, independently of the source of the initial BM (day 2, 3 or 4 post mortem), all of the animals were viable with 100% chimerism, and we obtained GFP+ leukocytes in all the different lineages.
Example VI. Anoxia and Low Temperature Enhance the Viability and Transplantation Potential of Stem Cells Isolated Post Mortem
[0244] To investigate the mechanism which confers the observed resistance of stem cells, the hostile environment occurring after death in a tissue i.e. hypoxia followed by anoxia was modeled. Culture conditions was established with a device usually used to culturing anaerobic bacteria (GenBag Chambers). The cells were maintained at 4 C. for various time intervals in the absence oxygen (less than 0.1% according to manufacturer). SCs isolated by FACS from Tg:Pax7-nGFP mice were maintained at 4 C. for 4, 7, 14 and 21 days in the absence oxygen (less than 0.1% according to manufacturer). Strikingly, it was observed that SCs better survived in a complete anoxic environment than in normoxic (20%) environment at 20 4 C. (see
[0245] Similar experiments were performed with hematopoietic stem cells isolated from mice post mortem and stored in the presence or absence of oxygen. BM cells were extracted from two femurs of Tg:CAG-GFP animals, kept at 4 C. for 1, 2, 3, or 4 days, and transplanted into lethally irradiated C57BL6 recipient mice (n5). Cell mortality in such conditions was important i.e. 63+/7% of cell loss compare to immediately after extraction after one day in anoxia, 79+/3% after two days in anoxia, 98+/1 after 3 days in anoxia and 96+/1 after 4 days in anoxia (
[0246] In summary, the inventors have shown in animal model that transplantation of skeletal muscle and hematopoietic stem cells obtained from cadavers by the method of the invention, or enriched from biological sample when maintained in the absence of oxygen are functional and contribute to the regeneration of their respective tissues.